Ketamir-2 is an oral NMDA receptor modulator designed to selectively engage a validated pain pathway while avoiding the dissociative and psychotomimetic effects associated with traditional NMDA receptor blockers.
Available treatments are used off-label for CIPN and generally provide limited relief. No therapy is FDA-approved specifically for CIPN.
CIPN can force changes to cancer treatment and significantly impact a patient’s quality of life.
Ketamir-2 is an oral, reduced-affinity NMDA receptor blocker designed to selectively engage the PCP site, with no meaningful binding at AMPA, kainate, sigma, glycine, or glutamate receptors.
No SAEs · No Grade 3+ events · No discontinuations due to adverse events
A randomized, double-blind, placebo-controlled crossover study designed to evaluate oral Ketamir-2 in patients with moderate-to-severe persistent CIPN.
Moderate-to-severe persistent CIPN
Explore Our Pipeline
Explore MIRA’s broader pipeline across pain and obesity.
